Trastornos de ansiedad

  1. Reyes Marrero, R. 1
  2. de Portugal Fernández del Rivero, E. 1
  1. 1 Servicio de Psiquiatría. Hospital General Universitario Gregorio Marañón, Madrid, España
Revue:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Année de publication: 2019

Titre de la publication: Enfermedades psiquiátricas (I)Ansiedad y trastornos disociativos

Serie: 12

Número: 84

Pages: 4911-4917

Type: Article

DOI: 10.1016/J.MED.2019.07.001 DIALNET GOOGLE SCHOLAR

D'autres publications dans: Medicine: Programa de Formación Médica Continuada Acreditado

Résumé

Anxiety is a common adaptive answer to conditions considered threats. When clinical criteria of intensity, frequency and functional decline of the patients are exceeded, anxiety becomes a disorder. Among them are panic disorders, agoraphobia and generalized anxiety disorder. Due their effectiveness, tolerability and lack of tolerance and dependence, selective serotonin reuptake inhibitor (SSRI) antidepressants or serotonin and norepinephrine reuptake inhibitors (SNRI) are the first-line treatment. Conversely, benzodiazepines, although frequently used for the treatment of acute control of anxiety, are not indicated for long-term management of anxiety.

Références bibliographiques

  • Alegría AA, Hasin DS, Nunes EV, Liu S-M, Davies C, Grant BF. Comorbidity of generalized anxiety disorder and substance use disorders: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 2010;71(9):1187-95.
  • Angst J, Gamma A, Baldwin DS, Ajdacic-Gross V, Rössler W. The generalized anxiety spectrum: prevalence, onset, course and outcome. Eur Arch Psychiatry Clin Neurosci. 2009;259(1):37-45.
  • Bados-López, A. Tratamientos psicológicos eficaces para la agorafobia. Psicothema. 2001;13(3):453-64.
  • Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JRT. Evidence based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxf). 2005;19(6):567-96.
  • Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327-35.
  • Bandelow B, Baldwin DS, Zwanzger P. Pharmacological treatment of panic disorder. Mod Trends Pharmacopsychiatry. 2013;29:128-43.
  • Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183-92.
  • Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93-107.
  • Bandelow PD med D-PB, Zohar J, Hollander E, Kasper S, Möller H-J. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders : First Revision. World J Biol Psychiatry. 2008;9(4):248-312.
  • Batelaan NM, de Graaf R, Penninx BWJH, van Balkom AJLM, Vollebergh WA, Beekman ATF. The 2 year prognosis of panic episodes in the general population. Psychol Med. 2010;40(1):147-57.
  • Behar E, DiMarco ID, Hekler EB, Mohlman J, Staples AM. Current theoretical models of generalized anxiety disorder (GAD): conceptual review and treatment implications. J Anxiety Disord. 2009;23(8):1011-23.
  • Caldirola D, Alciati A, Riva A, Perna G. Are there advances in pharmacotherapy for panic disorder? A systematic review of the past five years. Expert Opin Pharmacother. 2018;19(12):1357-68.
  • Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo controlled trials. Depress Anxiety. 2018;35(6):502-14.
  • Chambless DL, Milrod B, Porter E, Gallop R, McCarthy KS, Graf E. Prediction and moderation of improvement in cognitive behavioral and psychodynamic psychotherapy for panic disorder. J Consult Clin Psychol. 2017;85(8):803-13.
  • De Jonge P, Roest AM, Lim CCW, Florescu SE, Bromet EJ, Stein DJ. Cross national epidemiology of panic disorder and panic attacks in the world mental health surveys. Depress Anxiety. 2016;33(12):1155-77.
  • DuPont RL. Panic disorder and addiction: the clinical issues of comorbidity. Bull Menninger Clin. 1997;61(2)SupplA:A54-65.
  • Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev. 2007;(1):CD004364.
  • Goodwin RD, Faravelli C, Rosi S, Cosci F, Truglia E, de Graaf R. The epidemiology of panic disorder and agoraphobia in Europe. Eur Neuropsychopharmacol. 2005;15(4):435-43.
  • Goodwin H, Yiend J, Hirsch CR. Generalized Anxiety Disorder, worry and attention to threat: A systematic review. Clin Psychol Rev. 2017;54:107-22.
  • Goodwin RD, Roy-Byrne P. Panic and suicidal ideation and suicide at-tempts: results from the National Comorbidity Survey. Depress Anxiety. 2006;23(3):124-32.
  • Hawgood J, De Leo D. Anxiety disorders and suicidal behaviour: an update. Curr Opin Psychiatry. 2008;21(1):51-64.
  • Hirschfeld RMA. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. Prim Care Companion J Clin Psychiatry. 2001;3(6):244-54.
  • Imai H, Tajika A, Chen P, Pompoli A, Furukawa TA. Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. Cochrane Database Syst Rev. 2016;10:CD011170.
  • Kaczkurkin AN, Foa EB. Cognitive-behavioral therapy for anxiety disorders: an update on the empirical evidence. Dialogues Clin Neurosci. 2015;17(3):337-46.
  • Lijster JM de, Dierckx B, Utens EMWJ, Verhulst FC, Zieldorff C, Dieleman GC. The age of onset of anxiety disorders. Can J Psychiatry Rev Can Psychiatr. 2017;62(4):237-46.
  • Locke AB, Kirst N, Shultz CG. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. Am Fam Physician. 2015;91(9):617-24.
  • Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O, Salanti G. Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. Cochrane Database Syst Rev. 2016;4:CD011004.
  • Roy-Byrne PP, Cowley DS. Course and outcome in panic disorder: a review of recent follow up studies. Anxiety. 1994;1(4):151-60.
  • Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. Philadelphia: Wolters Kluwer; 2017. p. 4997.
  • Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013. Int J Epidemiol. 2014;43(2):476-93.
  • Stein DJ, Scott KM, De Jonge P, Kessler RC. Epidemiology of anxiety disorders: from surveys to nosology and back. Dialogues Clin Neurosci. 2017;19(2):127-36.
  • Thibaut F. Anxiety disorders: a review of current literature. Dialogues Clin Neurosci. 2017;19(2):87-8.
  • Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2011;21(9):655-79.
La source de données: Dialnet